2 results
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
Approved WMORecruiting
Currently, no robust clinical data are available comparing interventional ablation strategies in the setting of persistent AF with enlarged Atrium > 4 cm and longstanding persistent AF, which reflects a difficult to treat patient-subgroup.…